The National Institute of Allergy and Infectious Diseases (NIAID), with funding provided in whole or in part by the Biomedical Advanced Research and Development Agency, plans to fund organizations with demonstrated vaccine product development experience to produce a vaccine candidate either for a NIAID Category A or B Priority Pathogen or a candidate third generation anthrax vaccine. Sol. No. BAA-NIH-BARDA-NIAID-DMID-AI2007007. Respond by Jan. 22, 2008. Contact: Jordan Pulaski, contract specialist, 301-451-480-4675, jpulaski@niaid.nih.gov.
NIAID Issues BAA for Bio-Defense Vaccine Enhancement
SHARE:
